Cargando…
Trial watch: STING agonists in cancer therapy
Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors, most of which sense ectopic DNA species in the cytosol. In particular, STING ensu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466854/ https://www.ncbi.nlm.nih.gov/pubmed/32934881 http://dx.doi.org/10.1080/2162402X.2020.1777624 |
_version_ | 1783577903741534208 |
---|---|
author | Le Naour, Julie Zitvogel, Laurence Galluzzi, Lorenzo Vacchelli, Erika Kroemer, Guido |
author_facet | Le Naour, Julie Zitvogel, Laurence Galluzzi, Lorenzo Vacchelli, Erika Kroemer, Guido |
author_sort | Le Naour, Julie |
collection | PubMed |
description | Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors, most of which sense ectopic DNA species in the cytosol. In particular, STING ensures the production of type I interferon (IFN) in response to invading DNA viruses, bacterial pathogens, as well as DNA leaking from mitochondria or the nucleus (e.g., in cells exposed to chemotherapy or radiotherapy). As a type I IFN is critical for the initiation of anticancer immune responses, the pharmaceutical industry has generated molecules that directly activate STING for use in oncological indications. Such STING agonists are being tested in clinical trials with the rationale of activating STING in tumor cells or tumor-infiltrating immune cells (including dendritic cells) to elicit immunostimulatory effects, alone or in combination with a range of established chemotherapeutic and immunotherapeutic regimens. In this Trial Watch, we discuss preclinical evidence and accumulating clinical experience shaping the design of Phase I and Phase II trials that evaluate the safety and preliminary efficacy of STING agonists in cancer patients. |
format | Online Article Text |
id | pubmed-7466854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74668542020-09-14 Trial watch: STING agonists in cancer therapy Le Naour, Julie Zitvogel, Laurence Galluzzi, Lorenzo Vacchelli, Erika Kroemer, Guido Oncoimmunology Review Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors, most of which sense ectopic DNA species in the cytosol. In particular, STING ensures the production of type I interferon (IFN) in response to invading DNA viruses, bacterial pathogens, as well as DNA leaking from mitochondria or the nucleus (e.g., in cells exposed to chemotherapy or radiotherapy). As a type I IFN is critical for the initiation of anticancer immune responses, the pharmaceutical industry has generated molecules that directly activate STING for use in oncological indications. Such STING agonists are being tested in clinical trials with the rationale of activating STING in tumor cells or tumor-infiltrating immune cells (including dendritic cells) to elicit immunostimulatory effects, alone or in combination with a range of established chemotherapeutic and immunotherapeutic regimens. In this Trial Watch, we discuss preclinical evidence and accumulating clinical experience shaping the design of Phase I and Phase II trials that evaluate the safety and preliminary efficacy of STING agonists in cancer patients. Taylor & Francis 2020-06-16 /pmc/articles/PMC7466854/ /pubmed/32934881 http://dx.doi.org/10.1080/2162402X.2020.1777624 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Le Naour, Julie Zitvogel, Laurence Galluzzi, Lorenzo Vacchelli, Erika Kroemer, Guido Trial watch: STING agonists in cancer therapy |
title | Trial watch: STING agonists in cancer therapy |
title_full | Trial watch: STING agonists in cancer therapy |
title_fullStr | Trial watch: STING agonists in cancer therapy |
title_full_unstemmed | Trial watch: STING agonists in cancer therapy |
title_short | Trial watch: STING agonists in cancer therapy |
title_sort | trial watch: sting agonists in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466854/ https://www.ncbi.nlm.nih.gov/pubmed/32934881 http://dx.doi.org/10.1080/2162402X.2020.1777624 |
work_keys_str_mv | AT lenaourjulie trialwatchstingagonistsincancertherapy AT zitvogellaurence trialwatchstingagonistsincancertherapy AT galluzzilorenzo trialwatchstingagonistsincancertherapy AT vacchellierika trialwatchstingagonistsincancertherapy AT kroemerguido trialwatchstingagonistsincancertherapy |